6
7
8
.
.
.
.
Roher A. E., Lowenson J. D., Clarke S., Woods A. S., Cotter R. J., Gowing E., Ball M. J. (1993) Beta-Amyloid-(1-42) is a major component
of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.Proc Natl Acad Sci U S A;90:10836-10840.
Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. (1994) Visualization of Aβ42(43) and Aβ40 in senile plaques with end-
specific A beta monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron;13:45-53.
Vassar R., Kovacs D. M., Yan R., Wong P. C. (2009) The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell
Biology, Function, and Therapeutic Potential. J Neurosci;29:12787-12794.
9
1
Vassar R. (2001) The β-secretase, BACE: a prime drug target for Alzheimer's disease. J Mol Neurosci;17:157-170.
0. Egan M. F., Kost J., Tariot P. N., Aisen .P. S., Cummings J. L., Vellas B., Sur C., Mukai Y., Voss T., Furtek C., Mahoney. E., Mozley L. H.,
Vandenberghe R., Mo Y., Michelson D. (2018) Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease. N Engl J
Med;378:1691-1703.
11. Timmers M., Streffer J. R., Russu A., Tominaga Y., Shimizu H., Shiraishi A., Tatikola K., Smekens P., Börjesson-Hanson A., Andreasen N.,
Matias-Guiu J., Baquero M., Boada M., Tesseur I., Tritsmans L., Nueten L. V., Engelborghs S. (2018) Pharmacodynamics of atabecestat
(JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study.
Alzheimers Res Ther;10:85-103.
1
2. Honig L. S., Vellas B., Woodward M., Boada M., Bullock R., Borrie M., Hager K., Andreasen N., Scarpini E., Seifert H. L., Case M., Dean R.
A., Hake A., Sundell K., Hoffmann V. P., Carlson C., Khanna R., Mintun M., DeMattos R., Selzler K. J., Siemers E. (2018) Trial of
Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N Engl J Med;378:321-330.
13. Hu X., Das B., Hou H., He W., Yan R. (2018) BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves
cognitive functions. J Exp Med;215:927-940.
14. https://www.eisai.com/news/2018/news201858.html.
1
5. Niu Y., Ma C., Jin H., Xu F. R., Gao H., Liu P., Li Y., Wang C., Yang G., Xu P. (2012) The Discovery of Novel β-Secretase Inhibitors:
Pharmacophore Modeling, Virtual Screening and Docking Studies. Chem Biol Drug Des; 79:972-980.
6. Barman A., Prabhakar R. (2013) Elucidating the catalytic mechanism of β-secretase (BACE1): a quantum mechanics/molecular mechanics
1
1
1
1
(
QM/MM) approach. J Mol Graph Model;40:1-9.
7. Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A. K., Zhang X. C., Tang J. (2000) Structure of the protease domain of memapsin 2
β-secretase) complexed with inhibitor. Science; 290:150-153.
8. Patel S., Vuillard L., Cleasby A., Murray C. W., Yon J. (2004) Apo and inhibitor complex structures of BACE (β-secretase).J Mol Biol;343,
07-416.
9. Swahn B. M., Kolmodin K., ꢀarlstrꢁm S., von Berg S., Sꢁderman P., Holenz J. R., Berg S., ꢂindstrꢁm ꢃ., Sundstrꢁm M.; Turek D.,
ihlstrꢁm ꢃ., Slivo C., Andersson L., Pyring D., Rotticci D., Ohberg L., Kers A., Bogar K., von Kieseritzky F., Bergh M., Olsson L.L., Janson
J., Eketꢄꢅll S., Georgievska B., Jeppsson F., ꢆꢅlting. J. (2012) Design and synthesis of β-site amyloid precursor protein cleaving enzyme
BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides. J Med Chem; 55:9346-9361.
(
4
ꢀ
(
2
0. Gravenfors Y., Viklund J., Blid J., Ginman T., ꢀarlstrꢁm S., ꢀihlstrꢁm ꢃ, Kolmodin K., ꢂindstrꢁm ꢃ., von Berg S., von Kieseritzky F., Slivo C.,
Swahn B. M., Olsson L.L., Johansson P., Eketꢄꢅll S., ꢆꢅlting ꢃ., Jeppsson F., Strꢁmberg ꢀ., Janson J., Rahm F. (2012) New
aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain. J Med Chem;55:9297-9311.
1. Wyss D. F., Wang Y. S., Eaton H. L., Strickland C., Voigt J. H., Zhu Z., Stamford A. W. (2012) Combining NMR and X-ray crystallography
in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors. Top Curr Chem; 317,83−114.
2. Tadashi A., Sumiko M., Izumi A., Natsumi A., Toshio T., Yoshitada S., Mitsuo K. (2003) One-Pot Synthesis Using Supported Reagents
System KSCN/SiO2-RNH3OAc/Al2O3: Synthesis of 2‐ Aminothiazoles and N‐ Allylthioureas. Tetrahedron;62:3201-3213.
3. Hong L., Tang J. (2004) ꢆlap Position of ꢆree Memapsin 2 (β-Secretase), a Model for Flap Opening in Aspartic Protease Catalysis.
Biochemistry;43:4689-4695.
2
2
2
2
2
4. Di L., Kerns E. H., Fan K., McConnell O. J., Carter G. T. (2003) High throughput artificial membrane permeability assay for blood-brain
barrier. Eur J Med Chem;38:223-232.
5. Cumming J. N., Smith E. M., Wang L., Misiaszek J., Durkin J., Pan J., Iserloh U., Wu Y., Zhu Z., Strickland C., Voigt J., Chen X., Kennedy
M. E., Kuvelkar R., Hyde L. A., Cox K., Favreau L., Czarniecki M. F., Greenlee W. J., McKittrick B. A., Parker E. M., Stamford A. W. (2012)
Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Bioorg
Med Chem Lett;22:2444−2449.
2
6. Stamford A. W., Scott J. D., Li S. W., Babu S., Tadesse D., Hunter R., Wu Y., Misiaszek J., Cumming J. N., Gilbert E. J., Huang C.,
McKittrick B. A., Hong L., Guo T., Zhu Z., Strickland C., Orth P., Voigt J. H., Kennedy M. E., Chen X., Kuvelkar R., Hodgson R., Hyde L. A.,
Cox K., Favreau L., Parker E. M., Greenlee W. J. (2012) Discovery of an orally available, brain penetrant BACE1 inhibitor that affords
robust CNS Aβ reduction. ACS Med Chem Lett;3:897−902.
27. Bennett B. D., Babu-Khan. S.,Loeloff R., Louis J. C., Curran E., Citron M., Vassar R. (2000). Expression analysis of BACE2 in brain and
peripheral tissues. J Biol Chem;275:20647–20651
2
8. Koike M., Nakanishi H., Saftig P., Ezaki J., Isahara K., Ohsawa Y., Schulz-Schaeffer W., Watanabe T., Waguri S., Kametaka S., Shibata
M., Yamamoto K., Kominami E., Peters C., von Figura K., Uchiyama Y. (2000) Cathepsin D deficiency induces lysosomal storage with
ceroid lipofuscin in mouse CNS neurons. J Neurosci;20:6898–6906.
29. Hernandez-Rodríguez M., Correa-Basurto J., Gutierrez A., Vitorica J., Rosales-Hernandez M. C. (2016) Asp32 and Asp228 determine the
selective inhibition of BACE1 as shown by docking and molecular dynamics simulations. Eur J Med Chem;124:1142-1154.
This article is protected by copyright. All rights reserved.